New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 2, 2014
08:08 EDTABT, ALR, DHR, RHHBYAlere CEO departure sharpens focus on potential acquisition, says JMP Securities
After the CEO of Alere, Ron Zwanziger, resigned, JMP Securities thinks the resignation "brings the notion of Alere's potential acquisition front and center." The firm sees Alere as "a natural fit" for Roche (RHHBY), Abbott (ABT), or Danaher (DHR).
News For ALR;RHHBY;DHR;ABT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 5, 2015
07:12 EDTALRAlere reports preliminary Q1 non-GAAP EPS 57c, consensus 49c
Reports preliminary Q1 adjusted revenue $610.7M, consensus $612.93M. Reports preliminary Q1 organic growth of 2.6%. Reports preliminary Q1 organic growth, excluding North America influenza sales, of 0.5%.
May 4, 2015
18:04 EDTDHRAckman says market has difficult time analyzying 'platform companies'
Subscribe for More Information
07:26 EDTRHHBYWorldwide Business Research to hold a conference
BioNetwork East 2015 Partnering Conference is being held in Miami on May 4-6.
07:17 EDTABTAbbott has a conference call hosted by JPMorgan
JPMorgan Analyst Weinstein will host a conference call with CEO Miles White on May 8 at 11 am.
May 1, 2015
07:43 EDTRHHBYExpensive drugs drove over 25% of 2013 Medicare drug spending, WSJ says
Subscribe for More Information
April 28, 2015
07:43 EDTABTMead Johnson pushing for changes to WIC program, WSJ reports
The law authorizing the $6B per year WIC program providing food vouchers to women who are pregnant or have young children is up for renewal this year and formula makers, led by top U.S. maker Mead Johnson (MJN), are pushing for change, said The Wall Street Journal. Growth in the program has made it a money-losing venture for baby formula makers who essentially make no profit off formula sold to states as part of the program and Mead Johnson is pushing for changing eligibility requirements, thereby limiting or even shrinking the pool of recipients, the report noted. Other U.S. infant formula makers include Abbott (ABT) and Nestle (NSRGY). Reference Link
April 27, 2015
06:19 EDTRHHBYPharmceutical companies buy drugs and raises prices, WSJ reports
Subscribe for More Information
April 23, 2015
06:24 EDTDHRNetScout receives clearance for acquisition of Danaher Communications business
Subscribe for More Information
06:18 EDTDHRDanaher sees FY15 adjusted EPS $4.23-$4.33, consensus $4.33
Subscribe for More Information
06:18 EDTDHRDanaher sees Q2 EPS $1.01-$1.05, consensus $1.08
Subscribe for More Information
06:17 EDTDHRDanaher reports Q1 adjusted EPS 93c, consensus 93c
Subscribe for More Information
April 22, 2015
15:50 EDTDHRNotable companies reporting before tomorrow's open
Subscribe for More Information
09:26 EDTABTAbbott sees flat growth in Molecular Diagnostics business in Q2
Sees mid-single digit growth for Global Diagnostics growth in Q2. Sees low single digit growth for Global Vascular in Q2. Expects similar double digit growth in EPD in Q2.
09:21 EDTABTAbbott sees FY15 revenue growth to be in low single digits, consensus $20.71B
Subscribe for More Information
09:20 EDTABTAbbott sees Q2 EPS 49c-51c, consensus 52c
Subscribe for More Information
07:48 EDTABTAbbott reports Q1 Nutrition sales up 6.3% to $1.67B
Subscribe for More Information
07:46 EDTABTAbbott backs FY15 adjusted EPS $2.10-$2.20, consensus $2.14
Subscribe for More Information
07:45 EDTABTAbbott reports Q1 adjusted EPS 47c, consensus 42c
Subscribe for More Information
05:27 EDTRHHBYRoche sees FY15 core EPS to grow ahead of sales at constant exchange rates
Expects FY15 sales to grow low- to mid-single digit, at constant exchange rates. Roche expects to further increase its dividend in Swiss francs.
05:27 EDTRHHBYRoche reports Q1 group sales CHF 11.83B vs. CHF 11.50B
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use